Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinetics of LEAP2 in Man
NCT04897984Phase 1Completed
- Sponsor
- Gentofte Hospital
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liver-expressed antimicrobial peptide 2 in obesity, sponsored by Gentofte Hospital. Primary endpoint: Plasma concentrations of LEAP2. Started May 2021; status: completed.
02
Drugs
liver-expressed antimicrobial peptide 2
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04897984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04897984.